Carteolol
Clinical data | |
---|---|
Trade names | Ocupress |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a601078 |
Pregnancy category |
|
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% |
Metabolism | Hepatic, active with 8-hydrocarteolol |
Biological half-life | 6–8 hours |
Excretion | Renal (50-70%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H24N2O3 |
Molar mass | 292.373 g/mol |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Carteolol (trade names Cartrol, Ocupress, Teoptic, Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Poenglaucol, Singlauc) is a non-selective beta blocker used to treat glaucoma.
References
External links
- El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.". Drug Deliv. 13 (1): 55–9. PMID 16401594. doi:10.1080/10717540500309073.
- Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.". Cornea. 24 (2): 213–20. PMID 15725891. doi:10.1097/01.ico.0000141232.41343.9d.
- Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol. 26 (2): 131–6. PMID 12660585.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.